Who is the CEO of Accretion Pharmaceuticals Ltd?
- Answer Field
-
The CEO or key managerial personnel of Accretion Pharmaceuticals Ltd is Mr. Patel.
BAJAJ BROKING
Accretion Pharmaceuticals Limited, incorporated in 2012, is a fast-growing pharmaceutical company engaged in the manufacturing and marketing of a wide range of healthcare products. Its diverse portfolio includes tablets, capsules, oral liquids, oral powders (like sachets and dry syrups), and external preparations such as ointments, creams, gels, lotions, medicated shampoos, mouthwash, and dusting powders. The company not only serves direct markets but also offers contract and loan licence manufacturing for various third-party marketers. With operations primarily on a principal-to-principal basis, Accretion caters to a wide range of corporate clients, reflecting its strong presence in the pharmaceutical supply chain.
Headquartered in Sanand, Ahmedabad, Gujarat, Accretion Pharmaceuticals boasts ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certifications, highlighting its adherence to quality, safety, and environmental standards. Backed by a skilled leadership team and professional management, the company has extended its reach to over 20 countries, including regions in Africa, Southeast Asia, and the Middle East, showcasing its global ambitions and operational strength.
For more details, visit the Accretion Pharmaceuticals IPO page.
Details | Information |
IPO Date | May 14, 2025 to May 16, 2025 |
Issue Size | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
Price Band | ₹96 to ₹101 per share |
Lot Size | 1200 shares |
Listing At | NSE SME |
Market Maker | Gretex Share Broking Private Limited |
Purpose of the IPO
Purchase of machinery and equipment
Funding Working capital requirements
General Corporate Purpose
Event | Date |
---|---|
IPO Open Date | Wed, May 14, 2025 |
IPO Close Date | Fri, May 16, 2025 |
Tentative Allotment | Mon, May 19, 2025 |
Initiation of Refunds | Tue, May 20, 2025 |
Credit of Shares to Demat | Tue, May 20, 2025 |
Tentative Listing Date | Wed, May 21, 2025 |
Cut-off time for UPI mandate confirmation | 5 PM on May 16, 2025 |
Pricing & Lot Size of Accretion Pharmaceuticals IPO
Price Band for the IPO
₹96 to ₹101 per share
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 1200 | ₹1,21,200 |
Retail (Max) | 1 | 1200 | ₹1,21,200 |
HNI (Min) | 2 | 2,400 | ₹2,42,400 |
Online Application Process
Log in to Your Trading Account
Access your trading account through your broker’s platform.
Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Select Accretion Pharmaceuticals IPO
Find "Accretion Pharmaceuticals IPO" and click on the ‘Apply’ button.
Enter Application Details
Specify the number of lots (minimum lot size: 1200 shares) and the bid price within the range of ₹96 to ₹101 per share.
Provide Your UPI ID
Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.
Review and Submit
Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on May 16, 2025, to complete your application process.
Key Financial Metrics
Total Assets: Grew from ₹17.74 crore in FY22 to ₹39.99 crore as of December 2024.
Revenue: Reached ₹35.75 crore in FY24.
Profit After Tax (PAT): Stood at ₹5.24 crore for December 2024.
Net Worth: Increased from ₹3.08 crore in FY22 to ₹13.58 crore as of December 2024.
Reserves and Surplus: Recorded at ₹5.41 crore (Dec 2024), growing steadily over the years.
Total Borrowings: Stood at ₹13.79 crore in December 2024.
Recent Performance and Growth Prospects
The company has shown strong financial growth, with a notable increase in total assets over the last few years.
Revenue generation has been consistent, indicating healthy market demand and effective business operations.
Profitability has improved significantly, reflecting efficient cost management and operational performance.
The company’s net worth has seen a substantial rise, suggesting strengthened financial stability and investor confidence.
Reserves and surplus have been steadily growing, supporting the company’s long-term financial health and future expansion plans.
While the company does carry borrowings, its overall growth trajectory highlights a balanced approach to leveraging and investment.
Potential Risks of Investing in the IPO
High dependency on contract manufacturing: A large portion of Accretion Pharmaceuticals’ business comes from third-party contracts and loan licence manufacturing. Any loss or non-renewal of such contracts could impact revenue streams.
SME listing limitations: Since the IPO is being launched on the NSE SME platform, liquidity may be lower than mainboard listings, potentially resulting in limited exit opportunities for investors.
Opportunities and Growth Potential
Global market expansion: With its presence in over 20 countries and growing international demand, Accretion Pharmaceuticals is well-positioned to strengthen its global footprint and revenue base.
Robust infrastructure and compliance: The company’s ISO certifications and modern manufacturing facility in Gujarat reflect strong operational capabilities, helping it attract new clients and scale operations.
KPI | Values |
ROE | 72.47% |
ROCE | 36.73% |
Debt/Equity | 2.52 |
RoNW | 72.47% |
PAT Margin | 11.51 |
Price to Book Value | 7.55 |
Registrar | Lead Manager(s) |
---|---|
Kfin Technologies Limited | Jawa Capital Services Private Limited |
Company Address of Accretion Pharmaceuticals Ltd
Accretion Pharmaceuticals Limited
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals, Vasna Chacharvad
Sanand,
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/
Accretion Pharmaceuticals Limited has developed a wide-ranging healthcare portfolio and operates across domestic and international markets. Its business model incorporates both direct marketing and third-party manufacturing arrangements, supported by certified processes and operational infrastructure. The company’s financial metrics indicate an upward trend in key areas, including revenue, profit, and net worth.
With its proposed IPO on the NSE SME platform, the company intends to raise capital for machinery purchases, working capital, and general corporate needs. Investors may consider the IPO timeline, lot size, and associated risks before proceeding through the application process.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Accretion Pharmaceuticals IPO.
Share this article:
No result found
The CEO or key managerial personnel of Accretion Pharmaceuticals Ltd is Mr. Patel.
The IPO will open for subscription on May 14, 2025, and will close on May 16, 2025.
Accretion Pharmaceuticals Ltd is engaged in manufacturing and marketing tablets, capsules, oral liquids, powders, and external preparations. It also provides contract and loan licence manufacturing services. The business model, based on a mix of direct sales and B2B manufacturing, offers diversified revenue streams. Sustainability will depend on contract retention, regulatory compliance, and operational efficiency.
The issue size is 29,46,000 equity shares, aggregating up to ₹29.75 crore.
‘Pre-apply’ allows investors to place an IPO order before the official subscription window opens. Orders are queued and submitted automatically once the IPO opens, subject to UPI mandate approval.
You will receive confirmation after your UPI mandate is approved. Ensure that you authorise the mandate by 5 PM on May 16, 2025, for your application to be valid.
The lot size is 1200 shares. The minimum investment for retail investors is one lot, i.e., 1200 shares.
The tentative allotment date is May 19, 2025.
The registrar for the IPO is Kfin Technologies Limited.
As per the information available in the public domain and the Red Herring Prospectus, no governance issues or red flags have been officially reported.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading